Disappointing Provenge Sales Stir Doubts About Demand
This article was originally published in The Pink Sheet Daily
Withdrawing sales forecast and suffering a major blow to stock price, Dendreon notes difficulty in reaching community doctors.
You may also be interested in...
Strategy of focusing immunotherapy on urologists and earlier stage prostate cancer is paying off, says CEO James Caggiano, as Dendreon becomes a standalone company under Chinese conglomerate Sanpower
AstraZeneca buys out respiratory franchise from Actavis, which it had gained a year prior with its purchase of Forest. Mylan announced two deals Feb. 2, collaborating in COPD with Theravance and buying women’s health products from India’s Famy Care.
The dealmaking machine has proposed buying Dendreon’s assets, including prostate cancer immunotherapy Provenge, through a bankruptcy rummage sale.